Pliant Therapeutics vs Zentalis Pharmaceuticals
PLRX and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLRX and ZNTL compare
Zentalis Pharmaceuticals is the larger company, worth 2.8 times as much as Pliant Therapeutics ($122M against $43.2M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLRX | ZNTL |
|---|---|---|
| Size and price | ||
| Market cap | $43.2M | $122M |
| Share price | $0.697 | $1.70 |
| Change, 1 year | −61.3% | 26.9% |
| Change, 5 years | −95.4% | −97.8% |
| Beta (5Y) | 1.00 | 2.14 |
| Employees | 49 | 106 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× (better) | 0.6× |
| FCF yield | −155% | −110% (better) |
| Profitability | ||
| Return on equity | −55.3% (better) | −61.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −698.2× | – |
| Current ratio | 8.05 (better) | 7.33 |
| Altman Z-score | −7.99 | −6.54 (better) |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.7% | 66.1% |
| Held by insiders | 13.0% | 58.0% |
| Insider net buying, 12 months | −$164K | $12.8M (better) |
| Short interest, % of float | 9.1% | 16.7% |
Go deeper
- PLRX stock overview
- PLRX income statement
- PLRX valuation and score
- ZNTL stock overview
- ZNTL income statement
- ZNTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.